EPIGENETIC ALTERATIONS IN PATIENTS
WITH TYPE 2 DIABETES MELLITUS
Karachanak-Yankova S1,a, Dimova R2,a, Nikolova D1, Nesheva D1, Koprinarova M3,
Maslyankov S4, Tafradjiska R5, Gateva P6, Velizarova M7, Hammoudeh Z1, Stoynev N2,
Toncheva D1, Tankova T2, Dimova I1,*
*Corresponding Author: Ivanka Dimova, Associate Professor, Department of Medical Genetics, Medical University
Sofia, Zdrave str. 2, 1431 Sofia, Bulgaria. Tel: +359-2-91-72-735. E-mail: ivanka.i.dimova@ gmail.com
page: 15
|
|
REFERENCES
1. Robertson RP. Chronic oxidative stress as a central
mechanism for glucose toxicity in pancreatic
islet β cells in diabetes. J Biol Chem. 2004;
279(41): 42351-42354.
2. Hari Kumar KVS, Modi KD. Twins and endocrinology.
Indian J Endocrinol Metab. 2014;
18(Suppl 1): S48-S52.
3. Bramswig NC, Kaestner KH. Epigenetics and
diabetes treatment: An unrealized promise?
Trends Endocrinol Met. 2012; 23(6): 286-291.
4. Kommoju U, Reddy BM. Genetic etiology of
type 2 diabetes mellitus: A review. Int J Diab
Dev Ctries. 2011; 31(2): 51-64.
5. Lyssenko V, Laakso M. Genetic screening for the
risk of type 2 diabetes: Worthless or valuable?
[Research Support, Non-U.S. Gov’t Review].
Diabetes Care. 2013; 36(Suppl 2): S120-S126.
6. Zimmet P, Alberti KGMM, Shaw J. Global and
societal implications of the diabetes epidemic.
[10.1038/ 414782a]. Nature. 2001; 414(6865):
782-787.
7. Ling C, Groop L. Epigenetics: A molecular link
between environmental factors and type 2 diabetes.
Diabetes. 2009; 58(12): 2718-2725.
8. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard
A. An operational definition of epigenetics.
Gene Dev. 2009; 23(7): 781-783.
9. Bernstein BE, Meissner A, Lander ES. The mammalian
epigenome. Cell. 2007; 128(4): 669-681.
10. Tsai H-C, Baylin SB. Cancer epigenetics: Linking
basic biology to clinical medicine. Cell Res.
2011; 21(3): 502-517.
11. Patra SK, Deb M, Patra A. Molecular marks for
epigenetic identification of developmental and
cancer stem cells. Clin Epigenetics. 2011; 2(1):
27-53.
12. Klose RJ, Bird AP. Genomic DNA methylation:
the mark and its mediators. [Research
Support, Non-U.S. Gov’t Review]. Trends Biochem
Sci. 2006; 31(2): 89-97. doi: 10.1016/j.
tibs.2005.12.008.
13. Keating ST, El-Osta A. Epigenetic changes in
diabetes. [Research Support, Non-U.S. Gov’t
Review]. Clin Genet. 2013; 84(1): 1-10. doi:
10.1111/cge.12121.
14. Bird A. DNA methylation patterns and epigenetic
memory. [Research Support, Non-U.S. Gov’t
Review]. Genes Dev. 2002; 16(1): 6-21.
15. Clouaire T, Stancheva I. Methyl-CpG binding
proteins: Specialized transcriptional repressors
or structural components of chromatin? Cell Mol
Life Sci. 2008; 65(10): 1509-1522.
16. Chavali V, Tyagi N, Tyagi SC, Mishra PK.
MiR-133 as an epigenetic regulator of diabetic
heart failure. FASEB J. 2012; 26(1_MeetingAbstracts):
1057.1022.
17. Adela R, Banerjee SK. GDF-15 as a target and
biomarker for diabetes and cardiovascular diseases:
A translational prospective. J Diabetes Res.
2015; 2015: 4090842. doi: 101155/2015/490842.
18. Lindahl B. The story of growth differentiation
factor 15: another piece of the puzzle. Clin
Chem. 2013; 59(11): 1550-1552.
19. Wallentin L, Hijazi Z, Andersson U, Alexander
JH, De Caterina R, Hanna M, et al. Growth
differentiation factor 15, a marker of oxidative
stress and inflammation, for risk assessment in
patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fribrilation
(ARISTOTLE) trial. Circulation; 2014; 130(21):
1847-1858.
20. Al-Moghrabi N, Nofel A, Al-Yousef N, Madkhali
S, Bin Amer SM, Alaiya A, et al. The molecular
significance of methylated BRCA1 promoter in
white blood cells of cancer-free females. [Research
Support, Non-U.S. Gov’t]. BMC Cancer.
2014; 14: 830. doi: 10.1186/1471-2407-14-830.
21. Walker BA, Wardell CP, Chiecchio L, Smith EM,
Boyd KD, Neri A, et al. Aberrant global methylation
patterns affect the molecular pathogenesis
and prognosis of multiple myeloma. [Randomized
Controlled Trial Research Support, Non-
U.S. Gov’t]. Blood. 2011; 117(2): 553-562.
22. Brevetti G, Schiano V, Chiariello M. Cellular
adhesion molecules and peripheral arterial disease.
(Review). Vasc Med. 2006; 11(1); 39-47.
23. Park JG, Yoo JY, Jeong SJ, Choi JH, Lee MR,
Lee MN, et al. Peroxiredoxin 2 deficiency exacerbates
atherosclerosis in apolipoprotein Edeficient
mice. [Research Support, Non-U.S.
Gov’t]. Circ Res. 2011; 109(7): 739-749.
24. Brown CO, Schibler J, Fitzgerald MP, Singh N,
Salem K, Zhan F, et al. Scavenger receptor class
A member 3 (SCARA3) in disease progression
and therapy resistance in multiple myeloma.
Leukemia Res. 2013; 37(8): 963-969.
25. Scoumanne A, Chen X. Protein methylation:
A new regulator of the p53 tumor suppressor.
Histol Histopathol. 2008; 23(9): 1143-1149.
26. El-Serag HB, Hampel H, Javadi F. The association
between diabetes and hepatocellular carcinoma:
A systematic review of epidemiologic
evidence. Clin Gastroenterol Hepatol. 2006;
4(3): 369-380.
27. Friberg E, Orsini N, Mantzoros C, Wolk A. Diabetes
mellitus and risk of endometrial cancer: A
meta-analysis. Diabetologia. 2007; 50(7): 1365-
1374.
28. Huxley R, Ansary-Moghaddam A, Berrington de
Gonzalez A, Barzi F, Woodward M. Type-II diabetes
and pancreatic cancer: A meta-analysis of
36 studies. (Meta-Analysis). Br J Cancer. 2005;
92(11): 2076-2083.
29. Larsson S, Orsini N, Brismar K, Wolk A. Diabetes
mellitus and risk of bladder cancer: A metaanalysis.
Diabetologia. 2006; 49(12): 2819-2823.
30. Larsson S, Wolk A. Diabetes mellitus and incidence
of kidney cancer: A meta-analysis of
cohort studies. Diabetologia. 2011; 54(5): 1013-
1018.
31. Larsson SC, Orsini N, Wolk A. Diabetes mellitus
and risk of colorectal cancer: A meta-analysis. J
Natl Cancer I. 2005; 97(22): 1679-1687.
32. Larsson SC, Mantzoros CS, Wolk A. Diabetes
mellitus and risk of breast cancer: A meta analysis.
Int J Cancer. 2007; 121(4): 856-862.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
